Holdbrook Mark J. 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Mar 11, 2022
Insider Transaction Report
Form 4
Holdbrook Mark J.
V.P., Clinical Affairs
Transactions
- Award
Stock Option (right to buy)
2022-03-09+36,173→ 36,173 totalExercise: $19.59Exp: 2032-03-08→ Common Stock (36,173 underlying) - Award
Restricted Stock Units
2022-03-09+10,612→ 10,612 total→ Common Stock (10,612 underlying)
Footnotes (3)
- [F1]25% of the option shares shall vest on March 9, 2023, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the Reporting Person's continuous service.
- [F2]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
- [F3]25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.